Want to see PFE full AI Analyst Report?
PFE Stock Chart & Stats
$28.57
-$0.04(-0.16%)
At close: 4:00 PM EDT
$28.57
-$0.04(-0.16%)
Day’s Range― - ―
52-Week Range$23.58 - $28.75
Previous CloseN/A
Volume28.91M
Average Volume (3M)44.19M
Market Cap
$161.30B
Enterprise Value$190.23K
Total Cash (Recent Filing)$11.70B
Total Debt (Recent Filing)$63.19B
Price to Earnings (P/E)37.0
Beta0.45
Next Earnings
Nov 03, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend Yield6.14%
Share Statistics
EPS (TTM)0.76
Shares Outstanding5,699,674,000
10 Day Avg. Volume38,238,412
30 Day Avg. Volume44,193,922
Financial Highlights & Ratios
PEG Ratio-4.33
Price to Book (P/B)1.64
Price to Sales (P/S)2.26
P/FCF Ratio15.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$28.46Price Target Upside-0.40% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)2.97
Revenue Forecast (FY)$62.25B
Bulls Say, Bears Say
Bulls Say
Diversified Non-COVID Product GrowthGrowth from launched and acquired medicines, including Seagen assets, Padcev, NURTEC and Eliquis, supports a broader commercial base and helps reduce Pfizer’s long-term dependence on COVID products.
Pipeline And R&D ProductivityA large flow of approvals, readouts and pivotal starts improves the probability of future launches and label expansion. Progress in obesity, oncology and immunology provides potential replacement growth as older products lose exclusivity.
Strong Cash Generation And Efficiency ProgramPositive and improving free cash flow provides internal funding for R&D, debt service and dividends. Multi-year manufacturing and productivity savings could support margins and partially offset pricing, competition and exclusivity pressures.
Bears Say
Earnings Remain Below Historical PeakAlthough revenue has rebounded, earnings power remains far below the 2021–2022 peak and has been volatile. This indicates that recovery is incomplete and leaves results sensitive to portfolio mix, impairments and the pace of new-product growth.
Leverage And Loss-of-exclusivity PressureElevated leverage reduces financial flexibility while upcoming loss-of-exclusivity events may pressure cash flow and revenue. Maintaining dividends, investing in the pipeline and funding business development could constrain deleveraging.
Clinical And Regulatory Execution RiskThe failed trial and Oxbryta forecast removal demonstrate that pipeline and regulatory outcomes can materially reduce asset value. Repeated setbacks would weaken expected replacement revenue and increase pressure on Pfizer’s long-term growth transition.
Pfizer News
PFE FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest stock price was $23.58 and its highest was $28.75 in the past 12 months.
What is Pfizer’s market cap?
Pfizer’s market cap is $161.30B.
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is Nov 03, 2026 which is in 67 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Aug 04, 2026. The company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.682 by $0.088.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Overvalued.
Does Pfizer pay dividends?
Pfizer pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 6.14%. See more information on Pfizer dividends here
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is 0.76.
How many shares outstanding does Pfizer have?
Pfizer has 5,699,674,000 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $0.77 in its last earnings report, beating expectations of $0.682. Following the earnings report the stock price went up 1.518%.
Which hedge fund is a major shareholder of Pfizer?
Currently, no hedge funds are holding shares in PFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pfizer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.46 (-0.40% Downside)
$28.46 (-0.40% Downside)
Blogger Sentiment
Bullish
PFE Sentiment 86%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.49%
12-Months-Change
Fundamentals
Return on Equity
6.14%
Trailing 12-Months
Asset Growth
-2.41%
Trailing 12-Months
Company Description
Pfizer
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
PFE Company Deck
PFE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and strategic narrative: management beat Q2 revenue and adjusted EPS expectations, raised full-year revenue guidance, highlighted strong growth across launched and acquired products (notably Seagen assets, Padcev, NURTEC, and Eliquis), and outlined robust R&D progress (numerous readouts, pivotal starts and promising clinical data across obesity, oncology and immunology). At the same time, material near-term setbacks were disclosed: a Phase III SV miss that drove a $4.3 billion impairment and a GAAP loss, lower-than-expected COVID revenues (notably Paxlovid), removal of Oxbryta revenue from forecasts, and elevated near-term R&D spend. Management emphasized cost-savings initiatives (now targeting ~ $9.7B through 2029), maintained dividend commitments, and raised confidence in returning to growth by the end of the decade. Overall, positives (revenue/EPS beats, guidance raise, strong launched/acquired product growth, and significant pipeline progress) outweigh the material but specific negatives tied largely to one clinical readout and COVID variability.View all PFE earnings summariesPFE Revenue Breakdown
97.79% Biopharma
0.00% PC1
0.00% Pfizer Ignite
2.21% Other business activities
PFE Stock 12 Month Forecast
Average Price Target
$28.46
▼(-0.40% Downside)
Technical Analysis
Ownership Overview
0.02% Insiders
15.51% Mutual Funds
12.30% Other Institutional Investors
48.19% Public Companies and Individual Investors